1 week Ago By ABMN Staff
biote Corp. ( NASDAQ:BTMD – Get Free Report ) major shareholder Guines Llc bought 43,378 shares of biote stock in a transaction that occurred on Monday, April 7th. The stock was bought at an average price of $3.
15 per share, with a total value of $136,640.70. Following the purchase, the insider now owns 4,107,987 shares of the company’s stock, valued at $12,940,159.
05. This trade represents a 1.07 % increase in their position.
The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink . Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC. Guines Llc also recently made the following trade(s): biote Stock Performance BTMD stock opened at $3.
25 on Wednesday. biote Corp. has a 1-year low of $3.
04 and a 1-year high of $8.44. The business’s 50 day moving average is $4.
20 and its 200-day moving average is $5.25. The firm has a market cap of $177.
81 million, a P/E ratio of 12.50 and a beta of 1.17.
Institutional Trading of biote Wall Street Analyst Weigh In Separately, Craig Hallum decreased their target price on shares of biote from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Thursday, March 13th.
View Our Latest Analysis on BTMD biote Company Profile ( Get Free Report ) biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance.
The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. See Also Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter .
.
